SCHEMBL10067355

SCHEMBL10067355

Cc1c(C)n(CC(=O)N2CCCCC2)c2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.70
L3MBTL1 Q9Y468 2/20 0.70
GLA P06280 1/20 0.70
MAPT P10636 3/20 0.64
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
HSD17B10 Q99714 2/20 0.55
ALOX15 P16050 1/20 0.55
SIGMAR1 Q99720 1/20 0.54
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPK1 P28482 1/20 0.50
RAB9A P51151 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TP53 P04637 1/20 0.49
GAA P10253 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067354 1.00 LMNA (0.70) LMNAL3MBTL1GLAMAPTALDH1A1
SCHEMBL10067342 0.99 LMNA (0.72) LMNAL3MBTL1GLAMAPTALDH1A1
SCHEMBL10067353 0.85 NPSR1 (0.62) LMNAL3MBTL1GLAMAPTALDH1A1
SCHEMBL9776542 0.84 MAPT (0.71) LMNAL3MBTL1GLAMAPTALDH1A1
SCHEMBL10067347 0.80 TSHR (0.64) LMNAL3MBTL1GLAMAPTALDH1A1
SCHEMBL11601199 0.77 ALDH1A1 (0.71) L3MBTL1GLAMAPTALDH1A1KDM4E
SCHEMBL14448728 0.77 ALDH1A1 (0.62) LMNAGLAMAPTALDH1A1KDM4E
SCHEMBL11605552 0.76 ALDH1A1 (0.60) LMNAMAPTALDH1A1KDM4EHSD17B10
SCHEMBL29930246 0.75 GRIN2B (0.57) LMNAL3MBTL1GLAMAPTALDH1A1
SCHEMBL10067346 0.75 L3MBTL1 (0.67) LMNAL3MBTL1MAPTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 LMNA 1875/4885L3MBTL1 440/4885GLA 2359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.